LY03017

DRUG3 trials

Sponsors

Luye Pharma Group Ltd.

Conditions

Alzheimer's Disease PsychosisHallucinations and Delusions Associated With Alzheimer's Disease PsychosisHallucinations and Delusions Associated With Parkinson Disease PsychosisNegative Symptoms of SchizophreniaParkinson Disease Psychosis

Phase 1

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017

Not yet recruitingNCT06388551

Luye Pharma Group Ltd.Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia

Start: 2024-05-10End: 2025-03-30Target: 60Updated: 2024-04-29

Effect of Food and Age on the Pharmacokinetics of LY03017

Not yet recruitingNCT06793995

Luye Pharma Group Ltd.Alzheimer's Disease Psychosis, Negative Symptoms of Schizophrenia, Parkinson Disease Psychosis

Start: 2025-02-28End: 2025-10-31Target: 26Updated: 2025-01-27

A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

Not yet recruitingNCT06980207

Luye Pharma Group Ltd.Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia

Start: 2025-05-31End: 2025-10-31Target: 40Updated: 2025-05-20